BACKGROUND: Human papillomavirus high risk (HPV-HR) type 16 is a significant risk factor for head and neck cancers (HNC) independent of tobacco and alcohol. The purpose of this study was to determine whether antibody levels to the HPV-16 oncoproteins E6 and E7 measured in sera collected at baseline (BL) prior to treatment and at two post-treatment follow-up (FU) visits were associated with HNC risk factors or prognosis. METHODS: Presence of antibodies to HPV-16 E6 and E7 was evaluated in 109 newly diagnosed HNC cases with BL and FU blood samples, using the enzyme-linked immunosorbent assay (ELISA). RESULTS: HPV-16 E6 and/or E7 seropositive HNC cases were associated with higher risk in younger patients (≤ 55 years), more sexual partners (≥ 10), oropharyngeal cancer, worse stage at diagnosis, poorer grade, and nodal involvement. Between BL and FU (median = 8.3 months), there were decreased antibody levels for seropositive E6 (73% vs. 27%, p = 0.02) and seropositive E7 patients (65% vs. 35%, p = 0.09) with 5% of BL E6 and 35% of BL E7 seropositive patients converting to negative status at FU. Overall mortality (OM) was significantly worse among BL E6 seronegative patients than among BL seropositive patients (40.2% vs.13.6%, p = 0.01). There were no disease specific (DS) deaths among BL E6 seropositive vs. 24% in BL E6 seronegative patients (p = 0.01). BL E7 seronegative patients also had higher mortality than BL seropositive patients (OM: 38.2% vs. 20.0%, p = 0.04; DS: 22.5% vs. 5.6%, p = 0.07). CONCLUSION: These findings are the first to follow post-treatment OD levels of HPV-16 E6 and E7 in HNC and suggest that these HPV antibodies may be potential prognostic markers of survival in HNC patients.
BACKGROUND:Human papillomavirus high risk (HPV-HR) type 16 is a significant risk factor for head and neck cancers (HNC) independent of tobacco and alcohol. The purpose of this study was to determine whether antibody levels to the HPV-16 oncoproteins E6 and E7 measured in sera collected at baseline (BL) prior to treatment and at two post-treatment follow-up (FU) visits were associated with HNC risk factors or prognosis. METHODS: Presence of antibodies to HPV-16 E6 and E7 was evaluated in 109 newly diagnosed HNC cases with BL and FU blood samples, using the enzyme-linked immunosorbent assay (ELISA). RESULTS:HPV-16E6 and/or E7 seropositive HNC cases were associated with higher risk in younger patients (≤ 55 years), more sexual partners (≥ 10), oropharyngeal cancer, worse stage at diagnosis, poorer grade, and nodal involvement. Between BL and FU (median = 8.3 months), there were decreased antibody levels for seropositive E6 (73% vs. 27%, p = 0.02) and seropositive E7 patients (65% vs. 35%, p = 0.09) with 5% of BL E6 and 35% of BL E7 seropositive patients converting to negative status at FU. Overall mortality (OM) was significantly worse among BL E6 seronegative patients than among BL seropositive patients (40.2% vs.13.6%, p = 0.01). There were no disease specific (DS) deaths among BL E6 seropositive vs. 24% in BL E6 seronegative patients (p = 0.01). BL E7 seronegative patients also had higher mortality than BL seropositive patients (OM: 38.2% vs. 20.0%, p = 0.04; DS: 22.5% vs. 5.6%, p = 0.07). CONCLUSION: These findings are the first to follow post-treatment OD levels of HPV-16 E6 and E7 in HNC and suggest that these HPV antibodies may be potential prognostic markers of survival in HNC patients.
Authors: J Mork; A K Lie; E Glattre; G Hallmans; E Jellum; P Koskela; B Møller; E Pukkala; J T Schiller; L Youngman; M Lehtinen; J Dillner Journal: N Engl J Med Date: 2001-04-12 Impact factor: 91.245
Authors: Elaine M Smith; Justine M Ritchie; Michael Pawlita; Linda M Rubenstein; Thomas H Haugen; Lubomir P Turek; Eva Hamsikova Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396
Authors: Wei Li; Carol H Thompson; Christopher J O'Brien; Edward B McNeil; Richard A Scolyer; Yvonne E Cossart; Michael J Veness; D Murray Walker; Gary J Morgan; Barbara R Rose Journal: Int J Cancer Date: 2003-09-10 Impact factor: 7.396
Authors: Rolando Herrero; Xavier Castellsagué; Michael Pawlita; Jolanta Lissowska; Frank Kee; Prabda Balaram; Thangarajan Rajkumar; Hema Sridhar; Barbara Rose; Javier Pintos; Leticia Fernández; Ali Idris; María José Sánchez; Adoración Nieto; Renato Talamini; Alessandra Tavani; F Xavier Bosch; Ulrich Reidel; Peter J F Snijders; Chris J L M Meijer; Raphael Viscidi; Nubia Muñoz; Silvia Franceschi Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506
Authors: Matti Lehtinen; Michael Pawlita; Klaus Zumbach; Katherine Lie; Matti Hakama; Egil Jellum; Pentti Koskela; Tapio Luostarinen; Jorma Paavonen; Eero Pukkala; Eva Sigstad; Steinar Thoresen; Joakim Dillner Journal: Am J Obstet Gynecol Date: 2003-01 Impact factor: 8.661
Authors: Justine M Ritchie; Elaine M Smith; Kurt F Summersgill; Henry T Hoffman; Donghong Wang; Jens P Klussmann; Lubomir P Turek; Thomas H Haugen Journal: Int J Cancer Date: 2003-04-10 Impact factor: 7.396
Authors: S M Schwartz; J R Daling; D R Doody; G C Wipf; J J Carter; M M Madeleine; E J Mao; E D Fitzgibbons; S Huang; A M Beckmann; J K McDougall; D A Galloway Journal: J Natl Cancer Inst Date: 1998-11-04 Impact factor: 13.506
Authors: Elaine M Smith; Justine M Ritchie; Kurt F Summersgill; Jens P Klussmann; John H Lee; Donghong Wang; Thomas H Haugen; Lubomir P Turek Journal: Int J Cancer Date: 2004-02-20 Impact factor: 7.396
Authors: Krystle A Lang Kuhs; Aimée R Kreimer; Sumita Trivedi; Dana Holzinger; Michael Pawlita; Ruth M Pfeiffer; Sandra P Gibson; Nicole C Schmitt; Allan Hildesheim; Tim Waterboer; Robert L Ferris Journal: Cancer Date: 2017-09-26 Impact factor: 6.860
Authors: Rebecca R Laborde; Vivian W Wang; Todd M Smith; N Eric Olson; Steven M Olsen; Joaquín J García; Kerry D Olsen; Eric J Moore; Jan L Kasperbauer; Nicole M Tombers; David I Smith Journal: Mayo Clin Proc Date: 2012-03 Impact factor: 7.616
Authors: Caihua Liang; Carmen J Marsit; Michael D McClean; Heather H Nelson; Brock C Christensen; Robert I Haddad; John R Clark; Richard O Wein; Gregory A Grillone; E Andres Houseman; Gordana Halec; Tim Waterboer; Michael Pawlita; Jeffrey F Krane; Karl T Kelsey Journal: Cancer Res Date: 2012-09-18 Impact factor: 12.701
Authors: Karen S Anderson; Garrick Wallstrom; Hilde Langseth; Marshall Posner; Julia N Cheng; Rizwan Alam; Diego Chowell; Ingegerd E Furre; Jon Mork Journal: Oral Oncol Date: 2017-09-01 Impact factor: 5.337
Authors: Yuehan Zhang; Tim Waterboer; Robert I Haddad; Brett A Miles; Alicia Wentz; Neil D Gross; Carole Fakhry; Harry Quon; Jochen H Lorch; Christine G Gourin; Daniel Clayburgh; Krzysztof J Misiukiewicz; Jeremy D Richmon; Peter E Andersen; Marshall R Posner; Gypsyamber D'Souza Journal: Oral Oncol Date: 2017-02-15 Impact factor: 5.337
Authors: Karen S Anderson; Kristina R Dahlstrom; Julia N Cheng; Rizwan Alam; Guojun Li; Qingyi Wei; Neil D Gross; Diego Chowell; Marshall Posner; Erich M Sturgis Journal: Oral Oncol Date: 2015-05-06 Impact factor: 5.337
Authors: Carole Fakhry; Jesse R Qualliotine; Zhe Zhang; Nishant Agrawal; Daria A Gaykalova; Justin A Bishop; Rathan M Subramaniam; Wayne M Koch; Christine H Chung; David W Eisele; Joseph Califano; Raphael P Viscidi Journal: Cancer Prev Res (Phila) Date: 2015-12-23